Related Experiment Video
Updated: Jan 7, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.8K
Is escalated BEACOPP dead? Rethinking standards in hodgkin lymphoma treatment.
Colette Hanna1, Fouad Attieh2, Hampig Raphaël Kourie3
1Faculty of Medicine, Lebanese American University Medical Center, Rizk Hospital, Zahar Street, 11-3288, Achrafieh, Beirut, Lebanon.
Medical Oncology (Northwood, London, England)
|December 11, 2025
Summary
Escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) is declining in Hodgkin lymphoma treatment due to toxicity. Novel therapies offer better efficacy with reduced side effects.
Area of Science:
- Oncology
- Hematology
- Clinical Therapeutics
Background:
- Escalated BEACOPP has been a standard for Hodgkin lymphoma, providing survival benefits.
- However, it is associated with significant toxicities like secondary malignancies and infertility.
Purpose of the Study:
- To examine the decline of escalated BEACOPP in Hodgkin lymphoma treatment.
- To highlight evolving therapy protocols and updated international guidelines.
Main Methods:
- Review of recent clinical trial data.
- Analysis of evolving Hodgkin lymphoma therapy protocols.
- Examination of international treatment guidelines.
Main Results:
- Novel therapies like Brentuximab Vedotin and immune checkpoint inhibitors show comparable or superior efficacy.
- These newer treatments significantly reduce toxicity compared to escalated BEACOPP.
- A shift in treatment paradigms is evident, with declining use of escalated BEACOPP.
Conclusions:
- Escalated BEACOPP use is decreasing in Hodgkin lymphoma management.
- Newer agents offer improved safety profiles and comparable efficacy.
- Challenges remain in the widespread adoption of novel therapies, including cost and accessibility.
